PAVmed enters $9.4 million at-the-market stock sale agreement with A.G.P./Alliance Global Partners
PAVmed Inc. signed a Sales Agreement with A.G.P./Alliance Global Partners that lets it sell common stock through the agent from time to time, up to $9,400,000 of shares under its current prospectus supplement. The company says it plans to use net proceeds for working capital and general corporate purposes, and the sales would dilute existing shareholders.
Key points
- Maximum offering under the current prospectus supplement is $9,400,000 of common stock.
- The agent's commission is 3.0% of aggregate gross sales prices, plus legal cost reimbursements of up to $65,000 at signing.
- Shares are offered under a Form S-3 shelf registration declared effective April 15, 2025, with a prospectus supplement dated September 9, 2026.
- Either party may terminate the agreement on ten business days' written notice.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 09, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.